SG11201401725SA - Fused tricyclic compounds as raf kinase inhibitors - Google Patents

Fused tricyclic compounds as raf kinase inhibitors

Info

Publication number
SG11201401725SA
SG11201401725SA SG11201401725SA SG11201401725SA SG11201401725SA SG 11201401725S A SG11201401725S A SG 11201401725SA SG 11201401725S A SG11201401725S A SG 11201401725SA SG 11201401725S A SG11201401725S A SG 11201401725SA SG 11201401725S A SG11201401725S A SG 11201401725SA
Authority
SG
Singapore
Prior art keywords
kinase inhibitors
raf kinase
tricyclic compounds
fused tricyclic
fused
Prior art date
Application number
SG11201401725SA
Other languages
English (en)
Inventor
Changyou Zhou
Shaohui Wang
Guoliang Zhang
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of SG11201401725SA publication Critical patent/SG11201401725SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201401725SA 2011-12-31 2011-12-31 Fused tricyclic compounds as raf kinase inhibitors SG11201401725SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/085146 WO2013097224A1 (fr) 2011-12-31 2011-12-31 Composés tricycliques fusionnés à utiliser en tant qu'inhibiteurs de la kinase raf

Publications (1)

Publication Number Publication Date
SG11201401725SA true SG11201401725SA (en) 2014-09-26

Family

ID=48696279

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401725SA SG11201401725SA (en) 2011-12-31 2011-12-31 Fused tricyclic compounds as raf kinase inhibitors

Country Status (28)

Country Link
US (3) US9273046B2 (fr)
EP (2) EP2797888B1 (fr)
JP (1) JP5868521B2 (fr)
KR (1) KR101713391B1 (fr)
CN (1) CN103596926B (fr)
AU (1) AU2011384857B2 (fr)
BR (1) BR112014013108B1 (fr)
CA (1) CA2856347C (fr)
CY (1) CY1118226T1 (fr)
DK (1) DK2797888T3 (fr)
EA (1) EA025597B1 (fr)
ES (1) ES2588775T3 (fr)
HR (1) HRP20160641T1 (fr)
HU (1) HUE029656T2 (fr)
IL (1) IL233364A (fr)
IN (1) IN2014DN06166A (fr)
LT (1) LT2797888T (fr)
ME (1) ME02529B (fr)
MX (1) MX352617B (fr)
NZ (1) NZ624068A (fr)
PL (1) PL2797888T3 (fr)
PT (1) PT2797888T (fr)
RS (1) RS55196B1 (fr)
SG (1) SG11201401725SA (fr)
SI (1) SI2797888T1 (fr)
SM (1) SMT201600302B (fr)
WO (1) WO2013097224A1 (fr)
ZA (1) ZA201405555B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2797888T3 (pl) 2011-12-31 2016-12-30 Połączone związki tricykliczne jako inhibitory kinazy raf
EP3013797B1 (fr) * 2013-06-28 2018-01-03 BeiGene, Ltd. Composés amides tricycliques condensés comme inhibiteurs de kinases multiples
EA029412B1 (ru) 2013-06-28 2018-03-30 Бейджин, Лтд. Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
WO2015089809A1 (fr) * 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Composés hétéroaryles substitués antidiabétiques
WO2015176267A1 (fr) * 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
GB201416186D0 (en) 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
CN113307805A (zh) * 2015-04-15 2021-08-27 百济神州有限公司 B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
JP6175519B2 (ja) * 2016-01-04 2017-08-09 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
KR20250117470A (ko) * 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
TWI849043B (zh) 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP4188552A2 (fr) 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Inhibiteurs de raf bicycliques fusionnés et leurs procédés d'utilisation
WO2022047145A1 (fr) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Composés de dégradation de protéine de fibrosarcome rapidement accéléré et leurs procédés d'utilisation
WO2022056368A1 (fr) 2020-09-14 2022-03-17 Arvinas Operations, Inc. Formes cristallines d'un composé pour la dégradation ciblée du récepteur des œstrogènes
JP2024504285A (ja) * 2020-12-29 2024-01-31 ティーエックスイノ バイオサイエンス インコーポレイテッド エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼの阻害活性を有する新規のナフチリジノン誘導体及びこれらの用途
US20240368109A1 (en) * 2021-09-21 2024-11-07 Merck Sharp & Dohme Llc Allosteric modulators of nicotinic acetylcholine receptors
WO2023212071A1 (fr) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Combinaison et utilisation associée
WO2023209611A1 (fr) 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Méthodes de traitement du cancer avec un inhibiteur du b-raf, en particulier le lifirafenib
WO2024054591A1 (fr) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068773A1 (fr) 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
US7767687B2 (en) * 2004-12-13 2010-08-03 Biogen Idec Ma Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
JP2008525355A (ja) 2004-12-23 2008-07-17 エフ．ホフマン−ラ ロシュ アーゲー ベンズアミド誘導体、これらの製造及び医薬剤としての使用。
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
CA2609299A1 (fr) 2005-05-20 2006-11-23 Array Biopharma Inc. Composes inhibiteurs raf et procedes d'utilisation de ceux-ci
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
WO2007027855A2 (fr) 2005-09-01 2007-03-08 Array Biopharma Inc. Composes inhibiteurs de la raf kinase et procedes d'utilisation de ceux-ci
WO2007067444A1 (fr) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Composes bicycliques ayant une activite inhibitrice de kinase
EP2021327B1 (fr) * 2006-05-15 2012-04-04 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
CN101528729A (zh) * 2006-08-23 2009-09-09 辉瑞产品公司 作为gsk-3抑制剂的嘧啶酮化合物
KR101104666B1 (ko) 2006-09-06 2012-01-13 에프. 호프만-라 로슈 아게 단백질 키나제 억제제로서의 헤테로아릴 유도체
EP2061761A1 (fr) 2006-09-07 2009-05-27 Millennium Pharmaceuticals, Inc. Dérivés de phénéthylamide avec une activité inhibitrice de kinase
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
KR20090130345A (ko) * 2007-05-04 2009-12-22 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications
US20100197924A1 (en) * 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
PL2797888T3 (pl) 2011-12-31 2016-12-30 Połączone związki tricykliczne jako inhibitory kinazy raf
CN113307805A (zh) 2015-04-15 2021-08-27 百济神州有限公司 B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途

Also Published As

Publication number Publication date
IL233364A (en) 2017-06-29
IN2014DN06166A (fr) 2015-08-21
EP3124472B1 (fr) 2018-07-25
LT2797888T (lt) 2016-10-10
HUE029656T2 (en) 2017-03-28
US9895376B2 (en) 2018-02-20
BR112014013108B1 (pt) 2020-11-24
HK1221222A1 (zh) 2017-05-26
AU2011384857A1 (en) 2014-05-29
BR112014013108A2 (pt) 2017-06-13
IL233364A0 (en) 2014-08-31
KR101713391B1 (ko) 2017-03-07
CN103596926B (zh) 2015-11-25
MX352617B (es) 2017-12-01
JP5868521B2 (ja) 2016-02-24
CN103596926A (zh) 2014-02-19
WO2013097224A1 (fr) 2013-07-04
SI2797888T1 (sl) 2017-01-31
NZ624068A (en) 2016-09-30
EP2797888B1 (fr) 2016-06-08
US20190000857A1 (en) 2019-01-03
EA201491305A1 (ru) 2015-04-30
CY1118226T1 (el) 2017-06-28
CA2856347C (fr) 2017-05-30
EA025597B1 (ru) 2017-01-30
AU2011384857B2 (en) 2016-03-03
KR20140108541A (ko) 2014-09-11
US10576087B2 (en) 2020-03-03
US9273046B2 (en) 2016-03-01
HRP20160641T1 (hr) 2016-09-23
US20160206621A1 (en) 2016-07-21
EP2797888A1 (fr) 2014-11-05
DK2797888T3 (en) 2016-09-19
ES2588775T3 (es) 2016-11-04
SMT201600302B (it) 2016-11-10
CA2856347A1 (fr) 2013-07-04
PT2797888T (pt) 2016-09-09
JP2015506353A (ja) 2015-03-02
RS55196B1 (sr) 2017-01-31
ME02529B (fr) 2017-02-20
PL2797888T3 (pl) 2016-12-30
US20150045355A1 (en) 2015-02-12
MX2014007829A (es) 2014-08-01
EP3124472A1 (fr) 2017-02-01
HK1192232A1 (zh) 2014-08-15
EP2797888A4 (fr) 2015-09-02
ZA201405555B (en) 2015-10-28

Similar Documents

Publication Publication Date Title
IL289834A (en) Conversion of tricyclic compounds as fgfr inhibitors
ZA201405555B (en) Fused tricyclic compounds as raf kinase inhibitors
IL245309B (en) Heterocyclic tricyclic compounds as jak inhibitors
ZA201501615B (en) Pyrazolopyrimidine compounds as kinase inhibitors
AP2013007252A0 (en) Heterocyclic compounds as kinase inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201309128B (en) Macrocyclic compounds as protein kinase inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2686317A4 (fr) Inhibiteurs des kinases raf
SG11201500973WA (en) Amino-quinolines as kinase inhibitors